Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Myriad Genetics (MYGN) Gross Profit: 2009-2025

Historic Gross Profit for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to $143.8 million.

  • Myriad Genetics' Gross Profit fell 4.01% to $143.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $580.7 million, marking a year-over-year increase of 12.43%. This contributed to the annual value of $585.4 million for FY2024, which is 13.23% up from last year.
  • Latest data reveals that Myriad Genetics reported Gross Profit of $143.8 million as of Q3 2025, which was down 5.27% from $151.8 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Gross Profit ranged from a high of $151.8 million in Q2 2025 and a low of $59.1 million during Q4 2022.
  • Moreover, its 3-year median value for Gross Profit was $137.6 million (2024), whereas its average is $134.5 million.
  • As far as peak fluctuations go, Myriad Genetics' Gross Profit surged by 131.80% in 2021, and later tumbled by 48.61% in 2022.
  • Myriad Genetics' Gross Profit (Quarterly) stood at $115.0 million in 2021, then plummeted by 48.61% to $59.1 million in 2022, then skyrocketed by 38.75% to $82.0 million in 2023, then spiked by 84.02% to $150.9 million in 2024, then declined by 4.01% to $143.8 million in 2025.
  • Its last three reported values are $143.8 million in Q3 2025, $151.8 million for Q2 2025, and $134.2 million during Q1 2025.